Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic modulator compositions
In an exclusive interview with The Fly, Axcella (AXLA) CEO Bill Hinshaw talked about the company, its pipeline, long COVID, the NASH opportunity and much more.
LONG COVID TRIAL: Axcella and Oxford University have started dosing long COVID patients in their Phase 2a clinical trial investigating AXA1125 as potential treatment for the debilitating symptoms of the disease. “The trial is going very well. We’ve initiated and started dosing patients. There is a tremendous interest both with patients as well with the medical community because unfortunately there are no proven options for patients with long COVID, there is very little in development and a tremendous need from a number standpoint – we now have 70M people globally estimated to have long COVID – fatigue is the most common symptom and has a huge impact both on society as they can’t return to work and a human element,” Axcella’s CEO Bill Hinshaw explained to The Fly. ” It’s a very large need and thus we’ve had a tremendous response and we’re on track to report our data in the middle of this year. We’re extremely excited and compelled by this need. ”
To see the rest of the story Click Here.